Our Team

Prior to joining OTD, Karen De Ceunynck was a Principal Scientist at the early-stage biotech company Summation Bio, where she led ex vivo and in vivo efforts of their non-viral gene therapy platform in multiple disease areas. Prior to that she was a Senior Scientist at Bioverativ, a Sanofi company, where she co-led a biologics drug discovery project in the rare bleeding disorders group. There Karen was responsible for in vitro and in vivo assay development and managing collaborations with other functions within Sanofi. Prior to that, Karen completed her postdoctoral fellowship at Beth Israel Deaconess Medical Center/ Harvard Medical school, where she researched how protecting the endothelium could reduce excessive clotting in sepsis. Karen earned her PhD in Biotechnology and Biochemistry from Catholic University Leuven (KU Leuven) in Belgium.